The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis

References

• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286.
   PubMed Web of Science ®Google Scholar
• Marrie RA. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol. 2017;13(6):375–382.
   PubMed Web of Science ®Google Scholar
• Krause I, Kern S, Horntrich A, et al. Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors. Mult Scler. 2013;19(13):1792–1799.
   PubMed Web of Science ®Google Scholar
• Moore P, Harding KE, Clarkson H, et al. Demographic and clinical factors associated with changes in employment in multiple sclerosis. Mult Scler. 2013;19(12):1647–1654.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–1136.
   PubMed Web of Science ®Google Scholar
• Paltamaa J, Sarasoja T, Wikstrom J, et al. Physical functioning in multiple sclerosis: a population-based study in central Finland. J Rehabil Med. 2006;38(6):339–345.
   PubMed Web of Science ®Google Scholar
• O’Connor RJ, Cano SJ, Ramió I Torrentà L, et al. Factors influencing work retention for people with multiple sclerosis: cross-sectional studies using qualitative and quantitative methods. J Neurol. 2005;252(8):892–896.
   PubMed Web of Science ®Google Scholar
• Pack TG, Szirony GM, Kushner JD, et al. Quality of life and employment in persons with multiple sclerosis. Work. 2014;49(2):281–287.
   PubMedGoogle Scholar
• Ivanova JI, Birnbaum HG, Samuels S, et al. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics. 2009;27(8):681–691.
   PubMed Web of Science ®Google Scholar
• Lad SP, Chapman CH, Vaninetti M, et al. Socioeconomic trends in hospitalization for multiple sclerosis. Neuroepidemiology. 2010;35(2):93–99.
   PubMed Web of Science ®Google Scholar
• Nicholas JA, Electricwala B, Lee LK, et al. Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data. BMC Neurol. 2019;19(1):258.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin Neurol. 2014;122:343–369.
   PubMedGoogle Scholar
• Salter A, Thomas N, Tyry T, et al. Employment and absenteeism in working-age persons with multiple sclerosis. J Med Econ. 2017;20(5):493–502.
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Bergman RE, Birnbaum HG, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;15(3):601–609.
   PubMedGoogle Scholar
• Yermakov S, Davis M, Calnan M, et al. Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis. J Med Econ. 2015;18(9):711–720.
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs. Curr Med Res Opin. 2009;25(4):869–877.
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Brook RA, Beren IA, et al. Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation. Curr Med Res Opin. 2011;27(1):179–188.
   PubMed Web of Science ®Google Scholar
• Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618–625.
   PubMedGoogle Scholar
• Capkun G, Lahoz R, Verdun E, et al. Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis. Curr Med Res Opin. 2015;31(5):1029–1039.
   PubMed Web of Science ®Google Scholar
• Marrie RA, Cohen J, Stuve O, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler. 2015;21(3):263–281.
   PubMed Web of Science ®Google Scholar
• Moccia M, Palladino R, Lanzillo R, et al. Predictors of the 10-year direct costs for treating multiple sclerosis. Acta Neurol Scand. 2017;135(5):522–528.
   PubMed Web of Science ®Google Scholar
• Chalmer TA, Buron M, Illes Z, et al. Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;91(1):67–74.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527–539.
   PubMed Web of Science ®Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22–33.
   PubMed Web of Science ®Google Scholar
• Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1–9.
   PubMed Web of Science ®Google Scholar
• Vieira MC, Conway D, Cox GM, et al. Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study. Curr Med Res Opin. 2020;36(2):261–270.
   PubMed Web of Science ®Google Scholar
• Irony TZ. The "utility" in composite outcome measures: measuring what is important to patients. JAMA. 2017;318(18):1820–1821.
   PubMed Web of Science ®Google Scholar
• Parise H, Laliberte F, Lefebvre P, et al. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J Neurol Sci. 2013;330(1–2):71–77.
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Leong SA, Oster EF, et al. Cost of stress urinary incontinence: a claims data analysis. Pharmacoeconomics. 2004;22(2):95–105.
   PubMed Web of Science ®Google Scholar
• Moccia M, Tajani A, Acampora R, et al. Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: comparison between centre-based and local service healthcare delivery. PLoS One. 2019;14(9):e0222012.
   PubMed Web of Science ®Google Scholar
• Moccia M, Loperto I, Lanzillo R, et al. Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy). BMC Health Serv Res. 2020;20(1):797.
   PubMed Web of Science ®Google Scholar
• Lucchetta RC, Tonin FS, Borba HHL, et al. Disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis. CNS Drugs. 2018;32(9):813–826.
   PubMed Web of Science ®Google Scholar
• Siddiqui MK, Khurana IS, Budhia S, et al. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis. Curr Med Res Opin. 2018;34(8):1361–1371.
   PubMed Web of Science ®Google Scholar
• McCool R, Wilson K, Arber M, et al. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:55–61.
   PubMed Web of Science ®Google Scholar